RxDoctor Payments Data

Daniel Davis, MD

Emergency Medicine · Chester, MTNPI 1548204423

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. ZOLL Medical Corporation accounts for 81.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $129,851 and has fallen 85.1% since, to $19,362 in 2025. Among emergency medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$361,238in general payments, 2019–2025

Across 93 payments — averaging $3884.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Medical Corporation$293K
  • Philips North America LLC$26K
  • Masimo Corporation$24K
  • Covidien LP$17K
  • Stryker$795
  • Integra Lifesciences Corporation$158
  • plus $156 from 3 others

What the payments were for

  • Consulting fees$183,48551%
  • Speaking & faculty fees$101,98928%
  • Travel & lodging$41,02111%
  • Food & beverage$34,74310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$361,238 in reported general payments places this provider in the 95th percentile of 163 emergency medicine providers in Montana.

See all emergency medicine providers in Montana

Medicare billing

Part B allowed, 2024
$13,844
Medicare patients
49
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$22,546
EliquisApixaban40$21,326
FarxigaDapagliflozin Propanediol12$4,607
Methenamine Hippurate20$1,059
Metoprolol Succinate58$873
Potassium Chloride53$847
Losartan Potassium112$830
Fluticasone Propionate57$734
Levothyroxine Sodium72$723
Pantoprazole Sodium57$506
Tamsulosin Hcl52$493
Rosuvastatin Calcium48$436
Diclofenac Sodium37$362
Famotidine21$361
Gabapentin32$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$12$4,60712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 163 emergency medicine providers in Montana.

Other emergency medicine in Chester

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →